{{Chembox
| ImageFile = Fexinidazole.svg
| ImageSize = 250px
| IUPACName = 1-Methyl-2-{[4-(methylsulfanyl)phenoxy]<wbr />methyl}-5-nitro-1''H''-imidazole
| OtherNames = HOE 239

| Section1 = {{Chembox Identifiers
| CASNo = 59729-37-2
| CASNo_Ref = {{cascite|correct|CAS}}
| PubChem = 68792
| ChemSpiderID = 62032
| ChEMBL = 1631694
| UNII = 306ERL82IR
| SMILES = [O-][N+](=O)c1cnc(n1C)COc2ccc(SC)cc2
| InChI = 1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3
 }}

| Section2 = {{Chembox Properties
| C = 12 | H = 13 | N = 3 | O = 3 | S = 1
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = 
 }}

| Section3 = {{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
 }}
}}

'''Fexinidazole''' is an antiparasitic agent.<ref name=Raether>{{cite journal | pmid = 6411009 | year = 1983 | last1 = Raether | first1 = W | last2 = Seidenath | first2 = H | title = The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica | volume = 77 | issue = 1 | pages = 13–26 | journal = Annals of Tropical Medicine and Parasitology}}</ref>  It has activity against ''[[Trypanosoma cruzi]]'', ''[[Tritrichomonas foetus]]'', ''[[Trichomonas vaginalis]]'', ''[[Entamoeba histolytica]]'',<ref name=Raether/> ''[[Trypanosoma brucei]],''<ref name=Jennings>{{cite journal | pmid = 6636983 | year = 1983 | last1 = Jennings | first1 = FW | last2 = Urquhart | first2 = GM | title = The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice | volume = 69 | issue = 5 | pages = 577–581 | journal = Zeitschrift für Parasitenkunde | doi=10.1007/bf00926669}}</ref> and ''[[Leishmania donovani]]''.<ref name=Wyllie>{{cite journal | pmid = 22301556 | year = 2012 | last1 = Wyllie | first1 = S | last2 = Patterson | first2 = S | last3 = Stojanovski | first3 = L | last4 = Simeons | first4 = FRC | last5 = Norval | first5 = S | last6 = Kime | first6 = R | last7 = Read | first7 = RD | last8 = Fairlamb | first8 = AH |title = The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis | volume = 4 | issue = 119 | pages = 119re1 | journal = Science Translational Medicine | doi=10.1126/scitranslmed.3003326 | pmc=3457684}}</ref> The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.<ref name=Wyllie/><ref name=Sokolova>{{cite journal | pmid = 20439607 | year = 2010 | last1 = Sokolova | first1 = AY | last2 = Wyllie | first2 = S | last3 = Patterson | first3 = S | last4 = Oza | first4 = SL | last5 = Read | first5 = RD | last6 = Fairlamb | first6 = AH |title = Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis | volume = 54 | issue = 7 | pages = 2893–900 | journal = Antimicrobial Agents and Chemotherapy | doi=10.1128/AAC.00332-10 | pmc=2897277}}</ref>

Fexinidazole was discovered by the German pharmaceutical company [[Hoechst AG]], but its development as a pharmaceutical was halted in the 1980s.<ref>{{cite web | url = https://www.nytimes.com/2008/01/08/health/research/08slee.html | title = Jump-Start on Slow Trek to Treatment for a Disease | publisher = ''[[New York Times]]'' | date = January 8, 2008}}</ref>  Fexinidazole is now being studied through a collaboration between [[Sanofi]] and the [[Drugs for Neglected Diseases Initiative]] for the treatment of [[Chagas disease]] and [[human African trypanosomiasis]] (sleeping sickness).<ref>{{cite web | publisher = DNDi Newsletter | url = http://www.dndi.org/newsletters/n17/en/10_1.htm | title = Fexinidazole Progresses into Clinical Development | date = November 2009}}</ref><ref>{{cite web | title = Sanofi-aventis and DNDi enter into a Collaboration Agreement on a New Drug for Sleeping Sickness, Fexinidazole | publisher = DNDi | url = http://www.dndi.org/press-releases/458-sanofi-aventis-and-dndi-enter-into-a-collaboration-agreement-on-a-new-drug-for-sleeping-sickness-fexinidazole.html | date = May 18, 2009 }}</ref>  Fexinidazole is the first drug candidate for the treatment of advanced-stage sleeping sickness in thirty years.<ref>{{cite journal | pmid = 21200426 | year = 2010 | last1 = Torreele | first1 = E | last2 = Bourdin Trunz | first2 = B | last3 = Tweats | first3 = D | last4 = Kaiser | first4 = M | last5 = Brun | first5 = R | last6 = Mazué | first6 = G | last7 = Bray | first7 = MA | last8 = Pécoul | first8 = B | title = Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness | volume = 4 | issue = 12 | pages = e923 | doi = 10.1371/journal.pntd.0000923 | pmc = 3006138 | journal = PLOS Neglected Tropical Diseases | editor1-last = Boelaert | editor1-first = Marleen}}</ref>

==See also==
* [[GNF6702]]
* [[SCYX-7158]]

==References==
{{reflist}}

{{Excavata antiparasitics}}

[[Category:Antiparasitic agents]]
[[Category:Nitroimidazoles]]
[[Category:Phenol ethers]]
[[Category:Thioethers]]